Forkhead box p3 (Foxp3)-expressing regulatory T cells are key mediators of peripheral tolerance suppressing undesirable immune responses. Ectopic expression of Foxp3 confers regulatory T cell phenotype to conventional T cells, lending itself to therapeutic use in the prevention of autoimmunity and transplant rejection. Here, we show that adoptive transfer of polyclonal, wild-type T cells transduced with an inducible form of Foxp3 (iFoxp3) can be used to suppress immune responses on demand. In contrast to Foxp3-transduced cells, iFoxp3-transduced cells home “correctly” into secondary lymphoid organs, where they expand and participate in immune responses. Upon induction of iFoxp3, the cells assume regulatory T cell phenotype and start to suppress the response they initially partook in without causing systemic immunosuppression. We used this approach to suppress collagen-induced arthritis, in which conventional Foxp3-transduced cells failed to show any effect. This provides us with a generally applicable strategy to specifically halt immune responses on demand without prior knowledge of the antigens involved.
Autoimmune diseases come in many diverse forms—such as rheumatoid arthritis, type I diabetes, multiple sclerosis, and inflammatory bowel disease—yet all share the same underlying cause, the launch of a detrimental immune response. In healthy individuals, a specialized immune cell type called regulatory T cells prevents these undesirable immune responses. Here, we present a strategy to suppress undesirable immune responses using genetically modified proinflammatory T cells that participate in these inappropriate immune responses until they are activated with a drug. At this point, the genetic modification causes them to change their behavior to that of regulatory T cells. Using a mouse model, we demonstrate that this approach can be used to stop undesirable immune responses on demand with minimal intervention.
Citation: Andersen KG, Butcher T, Betz AG (2008) Specific Immunosuppression with Inducible Foxp3-Transduced Polyclonal T cells. PLoS Biol 6(11): e276. doi:10.1371/journal.pbio.0060276
Academic Editor: Philippa Marrack, National Jewish Medical and Research Center/Howard Hughes Medical Institute, United States of America
Received: July 25, 2008; Accepted: September 29, 2008; Published: November 11, 2008
Copyright: © 2008 Andersen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: KGA is recipient of a scholarship from the Carlsberg Foundation. All work was performed at the Laboratory of Molecular Biology and funded by the Medical Research Council and in part supported by the Arthritis Research Campaign (ARC; project grant 18297).
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: 4-OHT, 4-hydroxytamoxifen; CFA, complete Freund's adjuvant; cII, chicken collagen type II; CIA, collagen-induced arthritis; ERT2, mutated estrogen receptor sensitive to tamoxifen, but not estrogen; FACS, fluorescence-activated cell sorter; Foxp3, Forkhead box p3; GFP, green fluorescent protein; i.p., intraperitoneal; iFoxp3, inducible Foxp3; ova, ovalbumin; s.c., subcutaneous; SEM, standard error of the mean; TH, helper T cell; TH::iFoxp3, CD4+CD25− T cell transduced with iFoxp3; TH::Foxp3, CD4+CD25− T cell transduced with Foxp3; TH::control, CD4+CD25− T cell transduced with a control gene; TR, regulatory T cell
Transplant rejection and autoimmune diseases ranging from rheumatoid arthritis, type I diabetes, and multiple sclerosis to inflammatory bowel disease—as diverse as they might appear—all have the same underlying problem: the launch of an undesirable immune response . Equally similar are the current approaches to treat these conditions, which are generally based on drugs that lead to systemic immunosuppression . Thus, the induction of specific tolerance is seen as the “Holy Grail” of therapeutic approaches .
The discovery that the immune system evolved regulatory T (TR) cells to stop undesirable immune responses, such as autoimmunity  and the rejection of the fetus [5–7], is of obvious therapeutic promise . Indeed, TR cells have already been shown to be capable of fulfilling such functions . However, the translation of experimental findings into actual therapeutic approaches is hampered by a variety of problems. Under experimental conditions, antigen-specific tolerance can be achieved by using TR cells from TCR-transgenic animals or by ex vivo expansion of antigen-specific TR cells [9–11]. However, it is difficult to imagine how a TCR transgenic approach can be translated into a generally applicable therapy. The antigen-specific ex vivo expansion of TR cells [9–11], or in vivo conversion of helper T cells (TH) into TR cells , is more feasible, albeit still problematic. They not only rely on the knowledge of, or at least access to the antigens involved in the pathological immune response, but are also time consuming and complicated when applied in a therapeutic context [8,13].
There are also conceptual problems. The lack or malfunction of TR cells is suspected to be at the root of many autoimmune diseases [14,15]. In these cases, it might be impossible to obtain and expand functional, antigen-specific TR cells, as they may not exist in the host in the first place. In principle, this problem can be circumvented by the conversion of conventional T cells into TR cells, either by TGF-ß–mediated induction [16–18] or ectopic expression of the lineage factor Forkhead box p3 (Foxp3) (NP_473380) [19–21]. However, without enriching antigen-specific “induced TR cells,” this is likely to be of limited benefit and may lead to systemic immune-suppression [11,22–24]. A further problem with TGF-ß–induced TR cells is that their phenotype seems to be unstable [25,26], although the presence of retinoic acid appears to stabilize the conversion [27,28].
Here, we present a strategy to suppress undesirable immune responses in an antigen-specific fashion without prior knowledge of the antigens involved. We accomplish this by adoptive transfer of a small number of polyclonal TH cells transduced with a genetically engineered, inducible form of Foxp3 (iFoxp3). CD4+CD25− cells transduced with iFoxp3 (TH::iFoxp3) initially retain their “proinflammatory” phenotype. They home “correctly” into the secondary lymphoid organs and partake in immune responses. Once the TH::iFoxp3 cells have expanded in an antigen-specific fashion, they can be converted to TR cell phenotype on demand by inducing iFoxp3, thereby stopping the immune response they partook in.
Failure of Polyclonal TH::Foxp3 Cells to Suppress Collagen-Induced Arthritis
Encouraged by the initial finding that polyclonal CD4+CD25− T cells transduced with Foxp3 (TH::Foxp3) can prevent and treat colitis in lymphopenic animals [19,29], we, like others [23,30,31], set out to test whether this can be used as a general strategy to prevent and treat autoimmune diseases. To test this hypothesis, we used collagen-induced arthritis (CIA), which is a well-established murine model of human rheumatoid arthritis . To obtain TH::Foxp3 cells, we transduced CD4+CD25− T cells with a murine leukemia virus (MLV)-based retroviral vector carrying a Foxp3-IRES-GFP cassette (m6pg[Foxp3]) (Figure S1). We immunized male DBA/1 mice with chicken collagen type II (cII) in complete Freund's adjuvant (CFA). In this model, we observe the first clinical symptoms of arthritis on day 19 after immunization, with the average clinical score reaching a plateau around day 35. Injection of 1 × 106 TH::Foxp3 cells 1 d prior to immunization did not have any significant impact on the outcome of the arthritis. It neither delayed the time of disease onset, nor did it alter disease progression (Figure 1A). The failure of polyclonal TH::Foxp3 cells to show any beneficial effect on the outcome of CIA under these experimental conditions is in agreement with the findings of others  and led us to reassess the approach per se. Therefore, we decided to examine the homing, expansion, and participation of TH::Foxp3 cells in immune responses.
(A) Arthritis was induced on day 0 by immunization with cII in CFA. Mice that did not receive any further treatment (black, n = 27) and mice that received 1 × 106 TH::Foxp3 cells 1 d prior to immunization (red, n = 7) are shown. The average arthritis scores of all mice in the two groups are shown.
(B and C) Comparison of the homing behavior of (B) CFSE-labeled TH (black) and TR (red) cells and (C) GFP-expressing TH::control (black) and TH::Foxp3 (red) cells. A total of 1 × 106 cells were transferred into each mouse (TH, n = 3; TR, n = 3; control, n = 4; and Foxp3, n = 6), and the tissues were analyzed 48 h later by flow cytometry. The diagrams represent the percentage of cells in each tissue, calculated from the total number of cells recovered in all tissues together (1.2 × 105 ± 0.1 × 105 TH cells and 1.1 × 105 ± 0.2 × 105 TR cells; 8.3 × 104 ± 2.7 × 104 TH::control cells and 5.1 × 104 ± 0.9 × 104 TH::Foxp3: cells; values ± SEM). Error-bars represent the SEM.
Altered Homing Behavior of TH::Foxp3 Cells
The decision whether to launch or suppress an immune response is made within the secondary lymphoid organs . This makes “correct” homing of the adoptively transferred cells an essential requirement for cytotherapy, as otherwise their participation in immune responses might be severely limited.
We therefore compared the homing of TH::Foxp3 cells to that of m6pg[control]-transduced CD4+CD25− T (TH::control) cells (Figure S1) and freshly isolated CFSE-labeled CD4+CD25− (TH) cells or CD4+CD25+ (TR) cells. A total of 1 × 106 cells were injected into wild-type Balb/c mice. After 48 h, we isolated the lymphocytes from the various tissues and analyzed them by flow cytometry. The transferred cells were identified based on either their green fluorescent protein (GFP) coexpression or CFSE label. TH::control cells, like TR and TH cells, could be detected at comparable frequencies in blood, and inguinal and iliac lymph nodes, as well as the spleen (Figure 1B and 1C). In contrast, the homing of TH::Foxp3 cells into the lymph nodes appeared to be defective and their homing into the spleen slightly impaired. Instead, a large number of these cells could be found in the liver (Figure 1C). The data suggest that ectopic expression of Foxp3 substantially altered the homing behavior of the transduced cells.
Foxp3-Mediated Regulation of CD62L
The absence of T cells from the peripheral lymph nodes is one of the key features of CD62L-deficient (sell−/−) mice . CD62L (l-selectin) plays a key role in the homing of lymphocytes into these tissues by allowing their attachment to high endothelial venules . Activation of T cells leads to endoproteolytic shedding of CD62L from the surface of the cells, involving the matrix-metalloprotease Adam17 . Therefore, we investigated whether the altered homing behavior of TH::Foxp3 cells is due to Foxp3-mediated effects on the surface expression of CD62L.
We found that the majority of freshly isolated TH and TR cells are CD62Lhi (Figure 2A and 2B). Activation of the cells for 72 h with anti-CD3/anti-CD28/IL-2 led to a down-regulation of CD62L surface expression, which was more marked in TR than TH cells (Figures 2C and S2A). To assess whether this is due to an increase in Adam17 activity in TR cells, we activated freshly isolated splenocytes with PMA and compared the surface expression of CD62L on Foxp3+ (TR) and Foxp3− (TH) CD4+ T cells. The rate of CD62L shedding appeared to be very similar for both cell types and could be completely blocked by the Adam17 inhibitor TAPI-2 (Figure 2D). This suggests that an additional Adam17-independent mechanism in TR cells is responsible for the difference in CD62L surface expression observed upon activation of TR and TH cells.
(A–D) CD62L expression on CD4+Foxp3− TH cells (black) and CD4+Foxp3+ TR cells (red).
(A) Representative FACS profiles for CD62L expression on TH and TR cells prepared from spleen (n = 3 in each case) with unstained TH cells (grey) shown as control.
(B) Mean fluorescence intensity (MFI) of CD62L on TH and TR cells from indicated tissues (n = 2 in each case).
(C) Representative FACS profiles of CD4+CD25− TH (black) and CD4+CD25+ TR (red) cells activated for 72 h (n = 3 in each case).
(D) Total splenocytes were incubated in the absence of any treatment (solid line) or activated by addition of 100 ng/ml PMA in the presence (dashed line) or absence (dotted line) of 50 μM TAPI-2 (n = 3 in each case).
(E–I) CD62L expression in TH::control (black) and TH::Foxp3 cells (red). CD4+CD25− cells were activated for 36 h and transduced (0 h) with either m6p8[control] (black line; n = 3) or m6p8[Foxp3] (red line; n = 3). (E and F) Representative FACS profiles of CD62L expression on transduced cells at (E) 0 h and (F) 24 h after transduction.
(G) Percentage of CD62Lhi cells within the transduced populations in the presence (dashed line) or absence (solid line) of 50 μM TAPI-2.
(H) Amount of soluble CD62L in the supernatant measured by ELISA (representative of two independent experiments).
(I) Relative CD62L expression in CD4+CD25− TH and CD4+CD25+ TR cells (n = 3 in each case), as well as TH::control and TH::Foxp3 cells 48 h after transduction (n = 2 in each case) determined by qPCR and normalized to HPRT. Error bars represent the SEM.
To further investigate this, we examined CD62L expression in TH::Foxp3 cells. We transduced CD4+CD25− cells with either m6p8[Foxp3] or m6p8[control]. The cells carrying the vector were identified based on their coexpression of ratCD8α (Figure S1). Whereas TH::control cells exhibited some down-regulation of surface CD62L upon activation with anti-CD3/IL-2, this was substantially more marked in TH::Foxp3 cells (Figure 2E and 2F). For the first 24 h, TAPI-2 appeared to partially inhibit the loss of surface CD62L on TH::Foxp3 cells, but it did not halt the steady decrease in surface CD62L over an extended period of time (Figure 2G). The CD62L down-regulation in TH::control cells was accompanied by an accumulation of soluble CD62L in the culture supernatant. This was not the case for TH::Foxp3 cells (Figure 2H), suggesting that in these cells, CD62L surface expression is regulated by a mechanism other than shedding. As Foxp3 is known to be a transcriptional regulator [37–40], we investigated whether it affects CD62L transcription. The CD62L mRNA expression level was reduced in both TH::Foxp3 and TH::control cells compared to freshly isolated TH and TR cells (Figure 2I). However, the level of CD62L transcript was 7.2-fold lower in TH::Foxp3 cells than in TH::control cells. The data suggest that upon activation of the cells, CD62L is further down-regulated on a transcriptional level by Foxp3.
It is noteworthy that retroviral transduction requires at least some degree of activation of the cell to allow for transgene integration. In this context, the expression of Foxp3 led to a very marked and sustained down-regulation of surface CD62L expression. This is likely to be a major contributor to the altered homing behavior of TH::Foxp3 cells. Although the down-regulation of CD62L upon activation is similarly more evident in thymically derived TR cells than TH cells (Figure S2A and S2B), albeit less marked than in TH::Foxp3 (Figure 2I), it does not appear to interfere with the cells ability to home into peripheral lymph nodes (Figure S2C).
iFoxp3—an Engineered Inducible Lineage Factor
The “incorrect” homing of polyclonal TH::Foxp3 cells might well contribute to their lack of showing any beneficial effect in CIA  (Figure 1A) and other animal models of autoimmune disease . However, one might question whether our initial approach had any merit in the first place, since the transfer of polyclonal TH::Foxp3 cells will only marginally increase the number of suppressive cells that recognize a particular antigen. Indeed, treatment with polyclonal TH::Foxp3 cells more or less mimics polyclonal TR cell therapy, which in contrast to approaches using antigen-specific TR cells, appears to be of limited benefit [22–24,41].
We decided to develop an alternative strategy, allowing us to convert the lineage commitment of conventional TH cells to that of TR cells after their antigen-specific expansion in vivo. To achieve this, we created an inducible Foxp3 (iFoxp3) that is constitutively expressed, but only becomes functionally active upon induction. Polyclonal, primary TH cells transduced with iFoxp3 (TH::iFoxp3 cells) should act like conventional T cells, retain their homing behavior, participate in immune responses, and expand in an antigen-specific fashion. This antigen-specific in vivo expansion of TH::iFoxp3 cells should allow us to specifically switch off immune responses on demand by inducing iFoxp3.
We fused a modified estrogen receptor (ERT2) to the C-terminal end of Foxp3 and cloned it into the m6p vector (Figure 3A and 3B). ERT2 only responds to tamoxifen and its metabolites such as 4-hydroxytamoxifen (4-OHT), but not estrogen . In the absence of induction, iFoxp3 is retained in the cytoplasm and kept inactive by heat shock proteins binding to the ERT2 part of the fusion protein . To confirm the inducible nature of iFoxp3, we transduced CD4+CD25− cells with m6p carrying a GFP-tagged iFoxp3 (m6p8[GFP-iFoxp3]). This allowed us to assess the induction of iFoxp3 based on the translocation of the fusion protein from the cytoplasm into the nucleus. We induced iFoxp3 in vitro by exposure to 4-OHT for 48 h (Figure 3C) or in vivo after adoptive transfer of the transduced cells into wild-type Balb/c mice by intraperitoneal (i.p.) injections of tamoxifen (Figure 3D). In either case, iFoxp3 translocated into the nucleus in about 60%–70% of the transduced cells at the time of microscopic analysis, confirming its inducible nature.
(A) Diagram of iFoxp3 containing retroviral vectors m6pg[iFoxp3] either coexpressing GFP or a GPI-linked ratCD8 α-chain m6p8[iFoxp3], and m6p8[GFP-iFoxp3], which contains a fusion of GFP and iFoxp3.
(B) MFI of intracellular stain for Foxp3 in TH::Foxp3 and TH::iFoxp3 cells compared to CD4+ TR and TH cells (n = 2 in each case).
(C and D) Subcellular localization of GFP-iFoxp3 in TH::GFP-iFoxp3 cells (C) in vitro after 48 h in the presence or absence of 50 nM 4-OHT or (D) in vivo after three injections of tamoxifen or carrier.
(E–G) Gain of TR cell function upon induction of iFoxp3.
(E) Proliferation of TH::control, TH::Foxp3, and TH::iFoxp3 cells upon anti-CD3ε (0.6 μg/ml) stimulation measured by 3H-thymidine incorporation in the absence (white bars; n = 3 in each case) or presence of 50 nM 4-OHT (grey bars; n = 3 in each case).
(F) A total of 1 × 105 CFSE-labeled CD4+CD25− target T cells were cocultured with 1 × 105 TH::control, TH::Foxp3 or TH::iFoxp3 cells and activated with anti-CD3ε (0.6μg/ml) (n = 2 in each case). The proliferation of target cells was measured based on CFSE dilution after 72 h, and the percentage of cells that had undergone at least one cell cycle is shown. The assay was performed in the absence (white bars) or the presence (grey bars) of 50 nM 4-OHT added to the transduced cells 24 h prior to setup.
(G) MFI of CD25 48 h after transduction on TH::control, TH::Foxp3, and TH::iFoxp3 in the absence (white bars; n = 2 in each case) or presence of 50 nM 4-OHT (grey bars; n = 2 in each case).
(H and I) Comparison of CD62L expression on TH::control, TH::Foxp3, and TH::iFoxp3 48 h after transduction with m6p8.
(H) Representative FACS profiles of CD62L expression (n = 2 in each case).
(I) Percentage of CD62Lhi cells within the transduced populations.
(J) Comparison of the homing behavior of TH::control (black) and TH::iFoxp3 (red) cells. A total of 1 × 106 cells were transferred into each mouse (TH::control, n = 2; TH::iFoxp3, n = 3), and the tissues were analyzed 48 h later by flow cytometry. The diagrams represent the percentage of cells in each tissue calculated from the total number of cells recovered in all tissues together (5.4 × 105 ± 0.7 × 105 TH::control cells and 3.1 × 105 ± 0.4 × 105 TH::iFoxp3 cells; values ± SEM).
Induction of Suppressor Function in TH::iFoxp3 Cells
A key requirement for our strategy is that iFoxp3 can be used to induce TR cell phenotype on demand. We therefore tested TH::iFoxp3 cells for hallmark features of TR cells such as sustained up-regulation of CD25, in vitro anergy to anti-CD3-stimulation, and suppression of target cells  before and after induction of iFoxp3. Whereas TH::Foxp3 cells were anergic (Figure 3E), suppressed the proliferation of cocultured CD4+CD25− cells (Figure 3F), and exhibited up-regulation of CD25 (Figure 3G), TH::iFoxp3 cells did so only after induction of iFoxp3 with 4-OHT. This demonstrates that, at least in vitro, TH::iFoxp3 cells appear to behave like conventional TH cells and only assume the phenotype of TR cells upon the induction of iFoxp3.
TH::iFoxp3 Home Like Naive CD4+ T Cells
From our observations with TH::control cells, we already knew that transduction per se did not appear to alter the homing behavior of the cells (Figure 1B and 1C). Nevertheless, we wanted to verify that noninduced iFoxp3 neither changes the expression of CD62L nor significantly alters the homing behavior of the TH::iFoxp3 cells. We found that in the absence of iFoxp3 induction, CD62L expression remained unchanged in TH::iFoxp3 compared to TH::control cells (Figure 3H and 3I). This is in stark contrast to our observations made for TH::Foxp3 cells (Figure 2E to 2I). To assess the homing behavior of the cells, we used the same approach as described above. We found that the homing behavior of TH::iFoxp3 cells was comparable to that of TH::control cells (Figure 3J) and thus very similar to that of naive TH and TR cells (Figure 1B).
Antigen-Specific In Vivo Expansion of TH::iFoxp3 Cells
To assess whether TH::Foxp3 and TH::iFoxp3 cells expand upon antigenic challenge in vivo, we transferred transduced cells prepared from DO11.10xSCID/Balb/c mice that expressed an ovalbumin (ova)-specific TCR, into wild-type Balb/c mice. We transferred 5 × 104 cells containing a mixture of 2 × 104 TH::iFoxp3 cells and 3 × 104 nontransduced cells (transduction efficiency of 40%) with the transduced population being clearly identifiable based on the coexpression of GFP. TH::iFoxp3 cells expanded upon immunization with ova in CFA by a factor of 12 in the draining lymph nodes and by a factor of 37.5 in the spleen (Figure 4A). In contrast, TH::Foxp3 cells only exhibited a very modest expansion, by a factor of 3.6 in the lymph nodes and 4.4 in the spleen. This could have been due to the TH::Foxp3 cells suppressing the ova-specific immune response and thereby impeding their own expansion. However, the levels of ova-specific antibodies in the serum were the same, independent of whether the mice had received TH::Foxp3 or TH::iFoxp3 cells, suggesting this was not the case (Figure 4B). Our data demonstrates a clear expansion of TH::iFoxp3 cells, which is consistent with their participation in the immune response against ova. This in vivo expansion upon antigen exposure is considerably less marked in TH::Foxp3 cells.
(A–C) Balb/c mice received 2 × 104 TH::Foxp3 or TH::iFoxp3 cells prepared from DO11.10xSCID mice before being immunized s.c. with either ova in CFA (+ova) or CFA alone (−ova) (n = 3 in each case).
(A) The frequency of GFP+ cells was measured eight days after immunization and the relative expansion was calculated as %GFP+ (+ova) / %GFP+ (-ova).
(B) Total ova-specific antibodies in prebleeds (d0, white bars; n = 2 in each case) and 8 d after immunization (d8, grey bars; n = 3 in each case) in immunized and naive mice.
(C) Total splenocytes were isolated from mice that had received TH::iFoxp3 cells and were challenged with the indicated amounts of ova for 72 h in the absence (white bars) or presence (grey bars) of 50 nM 4-OHT. The total proliferation was measured by 3H-thymidine incorporation, and the relative proliferation was calculated as (+ova / (−ova).
(D and E) Mice received 1 × 106 polyclonal TH::iFoxp3 cells and were immunized s.c. with ova in CFA. A week later, various tissues were analyzed.
(D) The total number of recovered TH::iFoxp3 cells from immunized mice (red, n = 3) or nonimmunized mice (black, n = 3) was calculated.
(E) The relative number of endogenous and TH::iFoxp3 cells was calculated as a ratio between immunized and nonimmunized mice. All error bars represent SEM, and p-values were determined using an unpaired t-test.
Next, we investigated whether the in vivo expanded ova-specific TH::iFoxp3 cells can be induced to suppress the very same immune response they partook in. We isolated splenocytes from these mice and exposed them to ova ex vivo. Although, in the absence of induction of iFoxp3, we observed the expected antigen-induced recall proliferation, we could not detect any proliferation above background in the presence of 4-OHT (Figure 4C). This suggests that upon iFoxp3 induction, the expanded TH::iFoxp3 cells became anergic and suppressed the proliferation of the cotransferred, nontransduced DO11.10 T cells as well as any endogenous ova-specific T cells.
To assess to what degree polyclonal TH::iFoxp3 cells participate in an immune response, we transferred 1 × 106 wild-type TH::iFoxp3 cells into wild-type Balb/c mice. A week after immunization with ova, we analyzed the lymphocytes from various tissues by flow cytometry. Whereas the number of TH::iFoxp3 cells recovered from the blood, iliac lymph nodes, liver, and spleen did not appear to change upon antigenic challenge, we observed a marked increase in the inguinal lymph nodes of the immunized mice (Figure 4D). This indicates that some of the TH::iFoxp3 cells expanded in the draining lymph nodes (subcutaneous [s.c.] immunization into the flanks). However, the number of endogenous cells in the inguinal lymph nodes increased equally (Figure 4E), suggesting that both populations expand to a similar degree with their ratio remaining constant.
Switching Off Immune Responses
To test the potential of TH::iFoxp3 cells in suppressing autoimmune responses, we turned to the CIA model in which TH::Foxp3 cells had failed to show an effect (Figure 1A). We transferred 1–2 × 106 polyclonal TH::iFoxp3 cells into wild-type DBA/1 mice 1 d prior to immunization with cII in CFA. We induced iFoxp3 on day 15 after immunization, which lies between the peak of the T cell response to collagen around day 10 [44,45] and the onset of clinical symptoms around day 21 . Mice that had received TH::iFoxp3 cells but did not receive tamoxifen injections to induce iFoxp3 showed the first signs of arthritis on day 19, similar to the mice that received no transfer of cells (Figure 5A). This effect was specific to the antigenic challenge (cII in CFA) inducing the autoimmune response, as mice receiving these cells without immunization did not exhibit any overt signs of developing autoimmune disease (Figure S3). Remarkably, 23 out of 25 of the mice that had received TH::iFoxp3 cells and tamoxifen injections to induce iFoxp3 did not show any clinical signs of arthritis (scores <3; Figure 5B). This is in stark contrast to the other groups, in which the majority of animals developed arthritis (scores ≥3; Figure 5B). Whereas tamoxifen has been reported to have anti-inflammatory properties , we found that by itself, it had only a minor effect on the development of CIA (Figure 5A) and no effect on the activity of TH::control cells in vivo (Figure S4). Despite the clear suppression of the clinical signs of CIA, we could detect collagen-specific antibodies in the serum of the animals at day 52, irrespective of the treatment they had received (Figure S5).
(A and B) Arthritis was induced on day 0 by immunization with cII in CFA.
(A) Mice that received 1 × 106 TH::iFoxp3 cells (dark grey, n = 17), mice that did not receive any further treatment (black, n = 27), mice that received tamoxifen injections (light grey, n = 14), and mice that received 1 × 106 TH::iFoxp3 cells and tamoxifen injections to induce iFoxp3 (red, n = 25) are shown. The average arthritis scores of all mice in the groups are shown for each day.
(B) Maximum arthritis score reached by individual animals that had received no transfer of cells, TH::Foxp3 cells (see Figure 1A), and TH::iFoxp3 cells ± tam. tam, tamoxifen.
(C and D) Arthritis was induced by immunization with cII in CFA.
(C) Mice that had received 1 × 106 TH::iFoxp3 cells the day before cII immunization and tamoxifen injections (red, n = 4) when the mice reached a score of 3 (day 0) and mice that did not receive any further treatment (black, n = 9) are shown.
(D) Maximum arthritis score reached by individual animals. Error bars represent the SEM, and p-values were determined by Fisher's Exact Test.
Next, we investigated whether TH::iFoxp3 cells are capable of stopping already established CIA. To this end, we waited until the mice had reached a clinical score of 3 before inducing iFoxp3. The induction appeared to completely halt, if not reverse, CIA, leading to a decline in the average severity score (Figure 5C). None of the mice showed a further increase of symptoms after induction of iFoxp3 (Figure 5D).
Specificity of the Suppression
To assess whether the conversion of TH::iFoxp3 cells to TR cell phenotype causes systemic immunosuppression, we compared “ex vivo recall reactions” to the antigen used prior to the induction of iFoxp3 (cII) to that of an unrelated antigen (ova) injected after induction. The collagen-specific T cell proliferation measured for mice in which iFoxp3 had been induced was significantly lower than that of mice that had received no transfer of cells, albeit still higher than that of naive mice (Figure 6A). As we did not add tamoxifen to the ex vivo culture, this most likely reflects a lower number of cII-specific proinflammatory T cells in the animals that had received TH::iFoxp3 cells and tamoxifen induction, rather than a mere ex vivo suppressive effect of TH::iFoxp3 cells. Remarkably, we could not detect any difference in the T cell proliferation upon exposure to ova irrespective of whether the mice had received treatment or not (Figure 6B). This suggests that the suppression only affects immune responses in which the TH::iFoxp3 cells have had the opportunity to participate prior to induction of iFoxp3. Indeed, we were able to detect TH::iFoxp3 cells in the inflamed paw of cII-immunized mice, suggesting that in the absence of induction these cells can contribute to the inflammation (Figure S6) However, once converted, the TH::iFoxp3 cells, despite still being present (Figure S7A and S7B), seem to have lost the capacity to suppress further unrelated immunological challenges (Figure 6B). This suggests that the conversion of TH::iFoxp3 cells by induction of iFoxp3 does not lead to a systemic immunosuppression.
(A and B) Mice were immunized with cII in CFA on day 0. tam, tamoxifen.
(A) On day 35, ex vivo recall reactions to cII were performed on cells purified from mice that did not receive any further treatment (control, n = 10), mice that had received 1 × 106 TH::iFoxp3 cells and tamoxifen injections (TH::iFoxp3 + tam, n = 10), and naive mice (naive, n = 10).
(B) Some of the mice described in (A) were immunized on day 28 with ova, and ex vivo recall reactions to ova were performed in parallel (control, −ova: n = 3, +ova: n = 7; TH::iFoxp3 + tam, −ova: n = 3, +ova: n = 7; and naive, −ova: n = 5, +ova: n = 5).
(C) Mice were immunized simultaneously with cII and ova in CFA on day 0. Ex vivo antigen-specific recall reactions to ova (closed) and cII (half-closed) were performed on day 28. Mice that did not receive any further treatment (naive, n = 4), mice that received 1 × 106 TH::iFoxp3 cells and tamoxifen injections (TH::iFoxp3 + tam, n = 4), and mice that received 1 × 106 TH::iFoxp3 cells (TH::iFoxp3, n = 4) are shown. p-Values were determined using an unpaired t-test.
Having shown that induced TH::iFoxp3 cells do not suppress further unrelated immune responses postinduction, we wanted to investigate the suppressive activity of TH::iFoxp3 cells in a context in which both cII and ova are present prior to induction. We transferred 1 × 106 polyclonal TH::iFoxp3 cells into wild-type DBA/1 mice 1 d before immunization with a 1:1 mixture of ova and cII in CFA. We induced iFoxp3 on day 15 after immunization and assessed the antigen-induced proliferation of splenocytes prepared from these mice on day 28. The recall proliferation against ova and cII were comparable. Equally similar was the reduction in proliferation in the cases in which iFoxp3 was induced (Figure 6C). In combination, these results suggest that this approach enables selective suppression without affecting further unrelated immune responses after induction of iFoxp3.
TH::iFoxp3 Cell Longevity
It is noteworthy that we were able to detect TH::iFoxp3 cells 52 d after their transfer, independent of the level of arthritis and whether the mice had received tamoxifen treatment or not (Figure 7A and 7B). An analysis of various tissues revealed that TH::iFoxp3 cells in blood were only marginally reduced between day 17 and day 52 (Figure 7C and 7D), and could readily be detected in the auxiliary lymph nodes and spleen. Although this is likely to be of advantage with regard to actively suppressing immune responses, it poses the question whether continuous tamoxifen presence is required. Due to the long half-life of tamoxifen , a direct assessment of this in vivo is not feasible. However, in in vitro suppression assays, TH::iFoxp3 cells had completely lost their suppressive activity 72 h after withdrawal of 4-OHT (Figure 7E). To perform these experiments, we had to compensate for a marked reduction in the number of viable TH::iFoxp3 cells that could be recovered under these conditions. To formally address the effect of the withdrawal of 4-OHT on TH::iFoxp3 cell viability, we exposed the cells to 4-OHT for 48 h from the point of transduction and then cultured them for a further 48 h in the absence of 4-OHT. The number of viable cells was assessed by flow cytometry. Withdrawal of 4-OHT had no effect on TH::control cells, but led to a marked decrease in the number of TH::iFoxp3 cells (Figure 7F to 7H). This suggests, that once induced, TH::iFoxp3 cells die upon tamoxifen withdrawal, but it remains unclear how this translates into an in vivo context. Indeed, it might be desirable to incorporate a suicide gene  into the retroviral vector as this allows the removal of the transduced cells if desired (Figure S8).
(A) Representative FACS profiles of splenocytes purified from the indicated mice 52 d after transfer of 1 × 106 TH::iFoxp3 cells. tam, tamoxifen.
(B) Summary of the frequency of GFP+ cells in the spleen 52 d after transfer (n = 3 in each case).
(C) Representative FACS profiles of specified tissues 52 d after transfer of 2 × 106 TH::iFoxp3 cells (n = 4 in each case; for auxiliary lymph node [aux. LN], a pooled sample was analyzed).
(D) Summary of the frequency of TH::iFoxp3 cells in the various tissues 17 and 52 d after transfer.
(E–H) TH::iFoxp3 cell survival upon 4-OHT withdrawal (E). TH::control and TH::iFoxp3 were cultured in the continuous presence [+ > +] or absence [− >−] of 50 nM 4-OHT. In the case of [+ >−], 4-OHT was withdrawn for 72 h after an initial induction for 48 h, before their suppressive activity was measured. A total of 1 × 105 cells of the indicated populations were cocultured at a 1:1 ratio with 1 × 105 CD4+CD25− target cells in 96-well plates coated with anti-CD3ε [0.6 μg/ml]. The proliferation of the cells was measured after 72 h based on 3H-thymidine incorporation (n = 3 in each case). (F–H) TH::control and TH::iFoxp3 were cultured in the presence or absence of 4-OHT (50 nM) and anti-CD3ε (0.6 μg/ml). After 48 h, 4-OHT and anti-CD3ε was withdrawn. The viability of the cells was assessed by flow cytometry at 0 h, 24 h, and 48 h by measuring the coexpression of GFP.
(F) Ratio of cells after 4-OHT withdrawal and cells that were cultured in the absence of 4-OHT from the start.
(G and H) Representative FACS profiles of TH::control and TH::iFoxp3 cells. All error bars represent the SEM.
Here, we have presented an approach that allows us to stop undesirable immune responses without prior knowledge of the antigens involved. TH::iFoxp3 cells participate in immune responses as conventional TH cells until iFoxp3 is induced. At this point, they change their phenotype from that of proinflammatory T cells to that of regulatory T cells and suppress the response they partook in.
Ectopic expression of Foxp3 in conventional T cells leads to their conversion into cells with TR-like phenotype [19–21]. It was demonstrated early on that these TH::Foxp3 cells, like TR cells, could suppress the development of colitis in lymphopenic hosts [19,29]. However, it was noted that in this context, the effectiveness of both polyclonal TH::Foxp3 cells and TR cells [29,50,51] might be due to the regulation of homeostatic expansion of the cotransferred, proinflammatory cells, rather than to a true antigen-specific suppression [9,11,52]. Furthermore, adoptive transfer of polyclonal TR cells will only marginally increase the number of suppressive cells that recognize a particular antigen. Indeed, the use of polyclonal TR cell  or TH::Foxp3 populations [11,23] (Figure 1A) have been of limited efficacy, unless the immune pathology was caused by an absence of functional TR cells [20,53] or the experiments were performed in lymphopenic animals . The restrictions imposed by the low frequency of antigen-specific TR or TH::Foxp3 cells in polyclonal populations can be circumvented by ex vivo expansion of antigen-specific TR cells and TCR transgenic TH::Foxp3 cells [9–11,41]. Both approaches have been successfully exploited in mouse models to treat diabetes [23,24,54,55], arthritis , and experimental autoimmune encephalomyelitis (EAE) , as well as being used for the induction of transplantation tolerance [57,58]. Whereas TCR transgenic T cells are an invaluable research tool to improve our understanding of the regulation of immune responses [59,60], it is unclear to what degree they can be used in a therapeutic context. Ex vivo expansion of antigen-specific TR cells [9,11], or in vivo conversion of TH into TR cells , promises to be more applicable. However, these approaches are technically challenging, time consuming, and most importantly, require knowledge of or access to the antigens involved in the immune response to be suppressed [8,13].
Our study of TH::Foxp3 cells revealed a further problem. Whereas TH::Foxp3 cells appear to adopt the characteristics of TR cells in vitro, we found their homing to be altered from that of endogenous TR and TH cells. This hinders the TH::Foxp3 cells from mimicking the homing behavior of endogenous TR cells, which has been shown to be important for their suppressive function in vivo [61–63]. Those TH::Foxp3 cells that fail to home to the secondary lymphoid organs might not receive the required antigen priming  and thus fail to expand like endogenous TR cells . This might explain the difference in the efficacy of approaches that use polyclonal Foxp3+ cells and those that use antigen-selected or TCR transgenic Foxp3+ cells. The latter might circumvent the need for an antigen-specific expansion in vivo by ensuring that there are sufficient numbers of antigen-specific cells from the onset.
The activation-induced, Foxp3-mediated down-regulation of CD62L might well be a key factor in the exclusion of TH::Foxp3 cells from the peripheral lymph nodes since T cells from CD62L-deficient mice exhibit a similar phenotype [34,35]. Further, it has been shown that CD62Lhi polyclonal TR cells have a more potent protective effect in vivo . However, we cannot exclude that ectopic expression of Foxp3 also alters the expression of other homing receptors. Indeed, we found that the activation-induced down-regulation of CD62L in thymically derived TR and TH cells was not sufficient to exclude them from the peripheral lymph nodes.
Here, we present an approach that addresses these problems by transducing polyclonal, conventional T cells with a retroviral vector encoding a genetically engineered inducible form of Foxp3. TH::iFoxp3 cells retain their proinflammatory character and the ability to home to the lymph nodes. Those TH::iFoxp3 cells that recognize an antigen appear to participate in the immune response and expand. This in vivo expansion of antigen-specific TH::iFoxp3 cells circumvents the need for an ex vivo expansion and does not rely on any knowledge of the antigens involved. Upon induction of iFoxp3, the in vivo expanded, antigen-specific TH::iFoxp3 cells assume a TR cell-like phenotype and suppress the undesirable response they initially partook in. We were able to demonstrate the efficacy of our approach by specifically halting CIA in a mouse model. Importantly, TH::iFoxp3 cell-mediated suppression appears to be restricted to the specific response, which is ongoing at the time of induction of iFoxp3. Those TH::iFoxp3 cells that do not already participate in an immune response at the time of induction lose the capacity to suppress further unrelated immune responses despite still being present. Although we cannot exclude that other factors play a role, it appears that the antigen-specific expansion of the TH::iFoxp3 cells prior to induction is an integral part of the observed nonsystemic suppression. In a therapeutic context, it might be desirable to limit the exposure to tamoxifen to minimize possible side effects. Although it appears that most TH::iFoxp3 cells die upon withdrawal of tamoxifen, those that do survive lose their suppressive activity. To avoid possible deleterious effects, these “revertant” cells can be removed based on the incorporation of a suicide gene into the retroviral vector used for the delivery of iFoxp3.
We believe that this strategy of induced conversion of TH cells into cells with a TR cell-like phenotype using iFoxp3 is generally applicable and will allow us to stop a variety of undesirable immune responses.
Materials and Methods
Animals and cell preparations.
Balb/c and DBA/1 mice (8–12 wk old) were purchased from Charles River and Harlan. DO11.10xSCID mice on the Balb/c background were kindly provided by Caetano Reis e Sousa, CRUK. Animals were maintained under specific pathogen-free conditions. Expert animal technicians provided animal care in compliance with the relevant laws and institutional guidelines. Cells used for in vivo and ex vivo experiments were purified (>90% purity) using an AutoMACS (Miltenyi Biotec) as previously described . Flow cytometric analysis and proliferation assays were performed as described previously  using the following antibodies: ratCD8α (BD Bioscience), CD62L (BD Bioscience), CD4 (BD Bioscience), CD25 (BD Bioscience), and Foxp3 (eBioscience).
Retroviral vectors and transduction.
Foxp3 was amplified from total spleen cDNA and iFoxp3 was constructed by a C-terminal fusion of ERT2 in place of the stop codon. Both were cloned into m6p retroviral vectors coexpressing either GFP or a GPI-linked rat CD8α marker. For the measurement of in vivo translocation of iFoxp3, GFP was cloned in-frame with Foxp3 after the first five codons in the 5′-end  in order to produce GFP-iFoxp3. For the production of retroviral supernatant, 293eT cells were cotransfected with an equal amount of pCl-Eco packaging plasmid and the respective m6p retroviral construct. Supernatant was harvested at 36 h and 48 h after transfection, filtered, and then used immediately. For retroviral transduction, the freshly purified CD4+CD25− T cells were activated in the presence of plate-bound anti-CD3ε (0.6 μg/ml) (BD Bioscience) and 10 U/ml of recombinant mIL-2 (PeproTech). Cells were transduced at 24 h and 36 h after activation by resuspension in a 1:2 mixture of supernatant and complete medium (RPMI/10% FCS/10 μM β-mercaptoethanol/50 μg/ml gentamicin) supplemented with 10 U mIL-2 and 6 μg/ml protamine sulphate (Sigma) and 10 U/ml mIL2, followed by centrifugation at 600×g for 2 h at 32 °C. Six hours after transduction, cells were resuspended in complete medium containing 10 U mIL-2. A fixed ratio of transduced (50%–60% in all cases) and nontransduced cells was adoptively transferred into mice 72 h after the last transduction.
Collagen-induced arthritis and gene induction.
Male DBA/1 mice received 1–2 × 106 transduced cells intravenously (i.v.) (day −1) and were immunized intradermally (i.d.) with 100 μl of cII (Sigma,) dissolved in 10 mM acetic acid and emulsified (1 μg/μl) in CFA (DIFCO) the following day (day 0) . The mice were assessed (blinded) on a daily basis, and inflammation of the paws was scored as follows: grade 0—no swelling; grade 1—swelling in an individual joint; grade 2—swelling in more than one joint or mild inflammation of the paw; and grade 3—severe swelling of the entire paw and/or ankylosis. Each paw was graded, and all scores where totaled for a maximum score of 12 per mouse. Mice reaching a score of 8 or more were euthanized in accordance with restrictions imposed by UK legislation. For iFoxp3 induction, the mice were injected i.p. with 100 μl of tamoxifen (in a 10:1 mixture of sunflower oil:ethanol [10 μg/μl tamoxifen]) on days 15 and 16, and (in a 10:1 mixture of sunflower oil:ethanol [1 μg/μl tamoxifen]) on days 23, 29, 30, 36, and 43. Alternatively, iFoxp3 was induced once the mice had reached a score of 3 (day 0) by i.p. injections with 100 μl of tamoxifen (in a 10:1 mixture of sunflower oil:ethanol [10 μg/μl tamoxifen]) on days 1, 2, 9, and 16.
In vivo expansion of antigen-specific T cells and ova-specific suppression assay.
CD4+CD25− T cells were purified from 6–12-wk-old female SCIDxDO11.10 mice and transduced with Foxp3 or iFoxp3 as described above. Balb/c females received i.v. 5 × 104 of a 2:3 ratio of transduced and nontransduced cells. Three days later, each mouse was immunized s.c. with either ova (Sigma) in CFA (50 μg/mouse) or just with CFA. The mice were sacrificed and analyzed 8 d after immunization. For ova-specific suppression assays, total splenocytes were prepared as described , resuspended in complete medium, and then plated into round-bottom 96-well plates (density of 2 × 105 cells/well). iFoxp3 was induced by adding 50 nM 4-OHT (Sigma). Ova was added to the cells 16 h after induction. After 60 h, the cells were pulsed with 1 μCi of 3H-thymidine (Amersham), collected at 72 h with a Filtermate Harvester (Packard), and analyzed with a TopCount scintillation counter (Packard) according to the manufacturer's instructions.
Collagen- and ova-specific ex vivo recall reactions.
CIA and iFoxp3 induction was performed as described above. On day 28, some of the mice received ova in CFA s.c. into both flanks (100 μg/mouse). Total splenocytes were prepared on day 35 and plated into round-bottom 96-well plates at a density of 5 × 105 cells/well. Proliferation of the cells was measured 72 h after addition of either ova (100 μg/ml) or cII (100 μg/ml) as described above. Alternatively, mice were immunized simultaneously with ova and cII on day 0 by i.d. injection of a mixture of 100 μg of ova and 100 μg of cII in CFA. Recall reactions were performed on day 28 as described above at a density of 2 × 105 cells/well.
Elisa for the detection of collagen- and ova-specific antibodies.
Ninety-six–well flat-bottom plates (Nunc) were coated with either ova (50 μg/ml) or cII (2 μg/ml) at 4 °C for 16 h and blocked with 1% BSA in PBS for 1 h. A total of 50 μl of serial dilutions (starting at 1:50 for ova and 1:10,000 for cII) of mouse sera in PBS were incubated for 2 h. Biotin-conjugated IgG1, IgG2a, IgG2b, and IgG3 (BD Bioscience) were then applied for 2 h. For ova detection, IgM (BD Bioscience) was also included. The development of cII and ova-specific immunoglobulins was then measured using a DuoSet kit (R&D Systems) according to the manufacturer's instructions.
Real-time reverse transcriptase PCR.
Total RNA was extracted using an RNeasy kit (Qiagen) including DNaseI treatment (Invitrogen). cDNA was synthesized with Superscript II (Invitrogen) with random hexamer primers (Amersham) following the manufacturers instructions. Real-time PCR was performed using Taqman SYBR green PCR master mix (Applied Biosystems) with primers specific for Sell (CD62L) and Hprt. The sequences used were: Sell primers: 5′-ATG CAG TCC ATG GTA CCC AAC TCA-3′ and 5′-CTG CAG AAA CAC AGT GTG GAG CAT-3′; Hprt primers: 5′-TTA AGC AGT ACA GCC CCA AAA TG-3′ and 5′-CAA ACT TGT CTG GAA TTT CAA ATC C-3′. An ABI Prism 7900 sequence detection system (Applied Biosystems) was used for 45 cycles of PCR according to the manufacturer's instructions.
Figure S1. Foxp3 and Control Retroviral Vectors
Diagram of Foxp3 containing retroviral vectors either coexpressing GFP (m6pg[iFoxp3]) or a GPI-linked ratCD8 α-chain (m6p8[iFoxp3]), and retroviral vectors containing blasticidine-S-deaminase (bsd) as a control gene either coexpressing GFP (m6pg[control]) or a GPI-linked ratCD8 α-chain (m6p8[control]).
(114 KB PDF)
Figure S2. Activation-Mediated Down-Regulation of CD62L in T Cells
(A and B) CD62L expression on CD4+CD25− TH cells (black) and CD4+CD25+ TR cells (red). (A) Representative fluorescence-activated cell sorter (FACS) profiles for CD62L expression on TH and TR cells prepared from spleen (n = 2) and activated with αCD3ε, αCD28, and IL-2 for the indicated length of time. (B) Representative graph of the relative mRNA levels of Sell (CD62L) in CD4+CD25− TH and CD4+CD25+ TR cells activated for the indicated length of time (n = 2) determined by quantitative PCR (qPCR) and normalized to Hprt.
(C) Comparison of the homing behavior of activated m6pg[control]-transduced CD4+CD25− TH (black, n = 8) and CD4+CD25+ TR (red, n = 8) cells. A total of 1 × 106 cells were transferred into each mouse, and the tissues were analyzed 48 h later by flow cytometry as described above.
(408 KB PDF)
Figure S3. Adoptive Transfer of TH::iFoxp3 Cells Does Not Lead to any Overt Signs of Autoimmune Disease
Balb/c mice received 2 × 106 TH::iFoxp3 cells (red, n = 7) or no cells (black, n = 5) and were visually inspected and weighed weekly for 11 wk.
(259 KB PDF)
Figure S4. Tamoxifen Treatment Has No Effect on TH::Control Cells In Vivo
Total splenocytes were isolated from mice that had received no transfer of cells or 1 × 106 polyclonal TH::control and were challenged with ova in CFA. Some of the mice were injected with tamoxifen on day 4 after immunization (n = 3 in all cases). The relative proliferation is shown as a ratio of thymidine incorporation in the presence or absence of ova stimulation in the recall reaction performed on day 7. All error bars represent the standard error of the mean (SEM), and the p-values were determined using an unpaired t-test.
(276 KB PDF)
Figure S5. Level of Collagen-Specific IgG Antibodies
Levels of collagen-specific IgG1, IgG2a, IgG2b, and IgG3 on day −2 and 52 in control mice (black, n = 6) and mice that had received TH::iFoxp3 cells and tamoxifen injections (red, n = 6). All error bars represent the SEM.
(131 KB PDF)
Figure S6. Migration of TH::iFoxp3 Cells into the Inflamed Paw
Mice received either 1 × 106 TH::iFoxp3 cells or no cell transfer (n = 2 in both cases). Arthritis was induced on day 0 by immunization with cII in CFA. The front and hind paws of arthritic mice were dissected on day 45, and the GFP+ cells were detected by flow cytometry. Error bars represent the SEM.
(260 KB PDF)
Figure S7. Survival of TH::iFoxp3 Cells in the Presence or Absence of Antigen
Mice received 1 × 106 polyclonal TH::iFoxp3 cells on day 0 and were immunized with ova as indicated on day 5. Some of the mice also received tamoxifen injections either on day 0 or day 8. The number of TH::iFoxp3 cells present in the spleen was assessed by flow cytometry based on GFP expression on day 13.
(A) Representative FACS profiles.
(B) Summary of the relative number of GFP+ cells in the spleen normalized to the total number of recovered cells (n = 3 in absence and n = 4 in the presence of ova immunization). All error bars represent the SEM.
(218 KB PDF)
Figure S8. In Vivo Depletion of TH::GFP/TK Cells
CD4+CD25− T cells were transduced with a retroviral vector containing GFP coexpressing a herpes simplex thymidine kinase gene (m6ptk[GFP]). Twenty-four hours after transduction, 1 × 106 cells were transferred into wild-type mice (day 0). Ganciclovir (1 mg/mouse) was administered for three consecutive days by i.p. injection; and on day 5, the inguinal lymph nodes and spleen were analyzed for the presence of TH::GFP/TK cells (n = 4 in all cases). All error bars represent the SEM.
(117 KB PDF)
We would like to thank Doug Fearon, Michael Neuberger, and Greg Winter for critical reading of the manuscript, and Felix Randow for provision of the retroviral vectors system as well as many helpful discussions. We would also like to thank Martin Reed, Sally Thomas, and Graham Ledger for expert animal care.
KGA and AGB conceived and designed the experiments. KGA, TB, and AGB performed the experiments. KGA and AGB analyzed the data. KGA and AGB wrote the paper.
- 1. Rioux JD, Abbas AK (2005) Paths to understanding the genetic basis of autoimmune disease. Nature 435: 584–589.
- 2. Gummert JF, Ikonen T, Morris RE (1999) Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10: 1366–1380.
- 3. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, et al. (2007) New reagents on the horizon for immune tolerance. Annu Rev Med 58: 329–346.
- 4. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–62562.
- 5. Aluvihare VR, Kallikourdis M, Betz AG (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5: 266–271.
- 6. Trowsdale J, Betz AG (2006) Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 7: 241–246.
- 7. Darrasse-Jeze G, Klatzmann D, Charlotte F, Salomon BL, Cohen JL (2006) CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. Immunol Lett 102: 106–109.
- 8. Bluestone JA, Thomson AW, Shevach EM, Weiner HL (2007) What does the future hold for cell-based tolerogenic therapy. Nat Rev Immunol 7: 650–654.
- 9. Bluestone JA (2005) Regulatory T-cell therapy: is it ready for the clinic. Nat Rev Immunol 5: 343–349.
- 10. von Boehmer H (2006) Can studies of tolerance ever lead to therapy. Ann Rheum Dis 65(Suppl 3): iii41–43.
- 11. Masteller EL, Tang Q, Bluestone JA (2006) Antigen-specific regulatory T cells–ex vivo expansion and therapeutic potential. Semin Immunol 18: 103–110.
- 12. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, et al. (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6: 1219–1227.
- 13. Kretschmer K, Heng TS, von Boehmer H (2006) De novo production of antigen-specific suppressor cells in vivo. Nat Protoc 1: 653–661.
- 14. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352.
- 15. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457–462.
- 16. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.
- 17. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875–1886.
- 18. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149–5153.
- 19. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061.
- 20. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.
- 21. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4: 337–342.
- 22. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM (2004) CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199: 1467–1477.
- 23. Jaeckel E, von Boehmer H, Manns MP (2005) Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54: 306–310.
- 24. Green EA, Choi Y, Flavell RA (2002) Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16: 183–191.
- 25. Floess S, Freyer J, Siewert C, Baron U, Olek S, et al. (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5: e38.. doi:10.1371/journal.pbio.0050038.
- 26. Selvaraj RK, Geiger TL (2007) A kinetic and dynamic analysis of foxp3 induced in T cells by TGF-beta. J Immunol 178: 7667–7677.
- 27. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, et al. (2007) Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256–260.
- 28. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, et al. (2007) Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204: 1775–1785.
- 29. Mottet C, Uhlig HH, Powrie F (2003) Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 170: 3939–3943.
- 30. Loser K, Hansen W, Apelt J, Balkow S, Buer J, et al. (2005) In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther 12: 1294–1304.
- 31. Fujio K, Okamoto A, Araki Y, Shoda H, Tahara H, et al. (2006) Gene therapy of arthritis with TCR isolated from the inflamed paw. J Immunol 177: 8140–8147.
- 32. Brand DD, Kang AH, Rosloniec EF (2003) Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 25: 3–18.
- 33. Boehm T, Bleul CC (2007) The evolutionary history of lymphoid organs. Nat Immunol 8: 131–135.
- 34. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, et al. (1994) Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1: 247–260.
- 35. Rosen SD (2004) Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol 22: 129–156.
- 36. Smalley DM, Ley K (2005) L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 9: 255–266.
- 37. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375–387.
- 38. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. (2007) Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446: 685–689.
- 39. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al. (2007) Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931–935.
- 40. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, et al. (2007) Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936–940.
- 41. Roncarolo MG, Battaglia M (2007) Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7: 585–598.
- 42. Feil R, Wagner J, Metzger D, Chambon P (1997) Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 237: 752–757.
- 43. Rossant J, McMahon A (1999) "Cre"-ating mouse mutants–a meeting review on conditional mouse genetics. Genes Dev 13: 142–145.
- 44. Pogue-Caley RR, McHeyzer-Williams MG (2001) Emergence of a type II collagen-specific helper T cell response. Eur J Immunol 31: 2362–2372.
- 45. Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF (2005) Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol 174: 3978–3985.
- 46. Rosloniec EF, Cremer M, Kang A, Myers LK (2001) Collagen-induced arthritis. Curr Protoc Immunol 15.5: 15.5.1–15.5.24.
- 47. Grainger DJ, Metcalfe JC (1996) Tamoxifen: teaching an old drug new tricks. Nat Med 2: 381–385.
- 48. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, et al. (2001) Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 10: 967–970.
- 49. Straathof KC, Spencer DM, Sutton RE, Rooney CM (2003) Suicide genes as safety switches in T lymphocytes. Cytotherapy 5: 227–230.
- 50. Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192: 295–302.
- 51. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, et al. (2005) Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 52: 2212–2221.
- 52. Li J, Bracht M, Shang X, Radewonuk J, Emmell E, et al. (2006) Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses. Cell Immunol 241: 75–84.
- 53. Asano M, Toda M, Sakaguchi N, Sakaguchi S (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184: 387–396.
- 54. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455–1465.
- 55. Tarbell KV, Petit L, Zuo X, Toy P, Luo X, et al. (2007) Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204: 191–201.
- 56. Hori S, Haury M, Coutinho A, Demengeot J (2002) Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A 99: 8213–8218.
- 57. Chai JG, Xue SA, Coe D, Addey C, Bartok I, et al. (2005) Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 79: 1310–1316.
- 58. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105: 4743–4748.
- 59. Bluthmann H, Kisielow P, Uematsu Y, Malissen M, Krimpenfort P, et al. (1988) T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes. Nature 334: 156–159.
- 60. Stefanova I, Dorfman JR, Germain RN (2002) Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420: 429–434.
- 61. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, et al. (2006) In vivo dynamics of regulatory T cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 109: 2649–2656.
- 62. Sather BD, Treuting P, Perdue N, Miazgowicz M, Fontenot JD, et al. (2007) Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 204: 1335–47.
- 63. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, et al. (2005) Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 174: 6993–7005.
- 64. Klein L, Khazaie K, von Boehmer H (2003) In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 100: 8886–8891.
- 65. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, et al. (2004) L-selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104: 3804–3812.
- 66. Kallikourdis M, Andersen KG, Welch KA, Betz AG (2006) Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus. Proc Natl Acad Sci U S A 104: 594–599.
- 67. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329–341.